These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29273611)

  • 21. Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration.
    Mann HJ; Demmon SL; Boelk DA; Payne CA; Effron MB; Rajagopalan N; Williams MD; Beck GM; Gopalrathnam G
    Am J Health Syst Pharm; 2004 Dec; 61(24):2664-71. PubMed ID: 15646701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
    Kumar A; Mann HJ
    Am J Health Syst Pharm; 2010 Oct; 67(19):1640-4. PubMed ID: 20852166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Mar; 51(5):672-8. PubMed ID: 8203388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stability of doripenem in polyvinyl chloride bags and elastomeric pumps.
    Crandon JL; Sutherland C; Nicolau DP
    Am J Health Syst Pharm; 2010 Sep; 67(18):1539-44. PubMed ID: 20811032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compatibility of amifostine with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1995 Oct; 52(20):2208-12. PubMed ID: 8564592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1996 May; 53(9):1041-5. PubMed ID: 8744467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
    Trissel LA; Gilbert DL; Martinez JF
    Am J Health Syst Pharm; 1997 Jan; 54(1):56-60. PubMed ID: 9117791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF; Gilbert DL
    Am J Health Syst Pharm; 1997 Aug; 54(15):1735-41. PubMed ID: 9262747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability and compatibility of topotecan hydrochloride with selected drugs.
    Mayron D; Gennaro AR
    Am J Health Syst Pharm; 1999 May; 56(9):875-81. PubMed ID: 10344611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compatibility screening of hextend during simulated y-site administration with other drugs.
    Trissel LA; Williams KY; Baker MB
    Int J Pharm Compd; 2001; 5(1):69-72. PubMed ID: 23981801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: evaluation of three methods.
    Alex S; Gupta SL; Minor JR; Turcovski-Corrales S; Gallelli JF; Taub D; Piscitelli SC
    Am J Health Syst Pharm; 1995 Nov; 52(21):2423-6. PubMed ID: 8564607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery.
    Condie CK; Tyler LS; Barker B; Canann DM
    Am J Health Syst Pharm; 2008 Mar; 65(5):454-7. PubMed ID: 18281738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Feb; 51(4):495-9. PubMed ID: 8017415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Jul; 51(14):1792-9. PubMed ID: 7942908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
    Kupie TC; Trusley C; Ben M; Trissel LA
    Am J Health Syst Pharm; 2008 Sep; 65(18):1735-59. PubMed ID: 18769000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compatibility of caspofungin acetate injection with other drugs simulated y-site coadministration.
    Chan P; Heatherly K; Kupiec TC; Trissel LA
    Int J Pharm Compd; 2008; 12(3):276-8. PubMed ID: 23969719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compatibility screening of precedex during simulated y-site administration with other drugs.
    Trissel LA; Saenz CA; Ingram DS; Williams KY; Retzinger JP
    Int J Pharm Compd; 2002; 6(3):230-3. PubMed ID: 23979190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
    Correard F; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Am J Health Syst Pharm; 2014 Aug; 71(15):1288-91. PubMed ID: 25027536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration.
    Karnatz NN; Wong J; Kesler H; Baaske DM; Speicher ER
    Am J Hosp Pharm; 1988 Feb; 45(2):368-71. PubMed ID: 2896460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compatibility of aztreonam with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1995 May; 52(10):1086-90. PubMed ID: 7656099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.